ChemomAb announces a peer reviewed publication of pre clinical proof of concept data supporting the pivotal role of CCL24 in systemic sclerosis and idiopathic pulmonary fibrosis. The paper “Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis” was published in May 2019 edition of “Annals of Rheumatoid Diseases” and supports the therapeutic potential of CM-101 for the treatment of patients with Systemic Sclerosis.
Annals of Rheumatoid Diseases is a top line peer reviewed journal which publishes basic, clinical and translational novel scientific research, owned by the European League Against Rheumatism (EULAR) and BMJ.
ChemomAb doses first subject in a phase 1 clinical trial of Subcutaneous injected CM-101 in healthy volunteers
ChemomAb to present “Attenuation of CCL24, using CM-101- a Novel monoclonal antibody, reduces cholangiocytes proliferation in experimental cholestasis models” at EASL International Liver Congress 2019.
ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease
ChemomAb appoints Bryan Jennings as Chief Financial Officer
ChemomAb to Present “CM101, A novel CCL24 blocking antibody, suppresses hepatic injury and fibrosis in experimental models of NASH and liver fibrosis” at AASLD international Liver meeting in San Francisco 2018
ChemomAb was granted an Orphan Drug Designation from the FDA for the treatment of Primary Sclerosis Cholangitis
ChemomAb appoints Dr. Stephen Squinto as Chairman of the Board:
ChemomAb presents “A novel CCL24 blocking monoclonal antibody ameliorates liver injury in experimental models of cholestasis” at EASL International Liver Congress 2018.
ChemomAb successfully completed Phase 1 in healthy volunteers, achieving its primary endpoint of safety, pharmacokinetics and pharmacodynamics.
ChemomAb completed a $10 million series B fund raising supported by Orbimed Israel, Peter Thiel, SBI Japan-Israel innovation Fund and Milestone venture.
ChemomAb to present ” CM-101, a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model” at AASLD’s Liver Meeting® 2017.
ChemomAb received OCS grant for the development of the CM101 program.
ChemomAb initiated its first in man clinical trial to test the safety, pharmacokinetic and pharmacodynamic profile of its lead drug CM101 in healthy volunteers.
ChemomAb presents “Circulating levels of the chemokine CCL24 and its receptor in patients with non-alcoholic fatty liver disease” in the Israeli Liver convention.
ChemomAb assembles advisory board meeting with Scleroderma key opinion leaders to discuss the outline of its clinical trial in Washington.
ChemomAb receives formal scientific advice from EMA for pre-clinical and clinical development of its lead first in class monoclonal antibody CM101.
ChemomAb orally presented “CM-101, A NOVEL MONOCLONAL ANTIBODY BLOCKING CCL24 AMELIORATES EXPERIMENTAL SYSTEMIC SCLEROSIS (SSC) AND IDIOPATHIC PULMONARY FIBROSIS (IPF) and A NOVEL ANTIBODY BLOCKING CCL24/CCR3 REDUCESCHEMOKINESIS OF IMMUNE CELLS AND THE TRANSITION OF FIBROBLASTS TO MYOFIBROBLASTS IN SYSTEMIC SCLEROSIS (SSC)” in the Systemic Sclerosis World Congress.
For further information published by Scleroderma News click here
ChemomAb is granted approval for its patent: ” Eotaxin-2 (CCL24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders ” in USA, Europe and Israel.
ChemomAb has engaged CMC Biologics for a full manufacturing program to generate GMP material for clinical trials.
ChemomAb received a second FDA approved orphan drug designation, for idiopathic pulmonary fibrosis treatment with CM101.
ChemomAb was granted orphan drug designation by the FDA, to treat systemic sclerosis patients with CM101.
ChemomAb received an orphan drug designation approval from the EMA for CM101 treatment in systemic sclerosis.